Share

Pierluigi Antonelli at the helm of Europe and Canada for the MSD Fertility business?

"I consider my appointment a tangible recognition of the qualities of the entire Italian team" comments Antonelli "qualities that have led us to excel in a complex market that requires professionalism, dedication, resilience, tenacity and a strong focus on patient needs".

Pierluigi Antonelli at the helm of Europe and Canada for the MSD Fertility business?

MSD Italia is pleased to announce that Pierluigi Antonelli has assumed the role of Fertility Business Unit Europe & Canada Lead in addition to the current responsibility of President and CEO of the Italian subsidiary MSD.

The creation of the EUCAN Fertility Business Unit represents an important step in building a stronger and more strategic organization; with the leadership of Antonelli - and thanks to an international work team - the area will be increasingly characterized by an innovative orientation, centered and focused on end users.

"I consider my appointment a tangible recognition of the qualities of the entire Italian team" comments Antonelli "qualities that have led us to excel in a complex market that requires professionalism, dedication, resilience, tenacity and a strong focus on patient needs". Indeed, Italy is considered one of the global centers of excellence in this area in terms of strategy, organizational model and results.  

"This appointment makes me particularly proud" continues Pierluigi Antonelli "I really care about the problem of infertility and I am aware of how much it is an intimate and delicate dimension, often painful, within a couple, and how much it is necessary to support these people by accompanying them on their journey towards the desired parenthood.”

For almost twenty years, MSD has been close to couples and the doctors who treat them with a complete product portfolio. Starting from the first treatments for infertility, such as Puregon and Orgalutran up to the latest generation therapies. MSD has developed cutting-edge strategies and boasts the innovation of Elonva (Corifollitropin alfa), the only once-weekly active ingredient capable of reducing the physical and psychological impact associated with commonly used daily treatments. 

MSD's innovation in fertility travels not only through pharmaceutical research but also through an offer of parallel services such as websites and apps for doctors in the fertility area. Pierluigi Antonelli will lead fertility teams in Canada and key European countries including France, Germany, Italy, Spain, Portugal, the Netherlands, Belgium, Austria, Switzerland, the United Kingdom, Ireland, Scandinavia, Greece, the Baltic States and the of central Europe. 

comments